UMB Bank n.a. Sells 609 Shares of Becton, Dickinson and Company (NYSE:BDX)

UMB Bank n.a. trimmed its holdings in shares of Becton, Dickinson and Company (NYSE:BDXFree Report) by 6.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,334 shares of the medical instruments supplier’s stock after selling 609 shares during the period. UMB Bank n.a.’s holdings in Becton, Dickinson and Company were worth $2,032,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. RVW Wealth LLC acquired a new position in shares of Becton, Dickinson and Company during the 3rd quarter worth about $52,000. Vest Financial LLC boosted its stake in shares of Becton, Dickinson and Company by 27.5% during the 4th quarter. Vest Financial LLC now owns 103,004 shares of the medical instruments supplier’s stock worth $25,115,000 after buying an additional 22,207 shares during the last quarter. M. Kulyk & Associates LLC boosted its stake in shares of Becton, Dickinson and Company by 5.1% during the 3rd quarter. M. Kulyk & Associates LLC now owns 16,640 shares of the medical instruments supplier’s stock worth $4,302,000 after buying an additional 809 shares during the last quarter. SG Americas Securities LLC lifted its stake in Becton, Dickinson and Company by 69.4% in the 4th quarter. SG Americas Securities LLC now owns 15,113 shares of the medical instruments supplier’s stock valued at $3,685,000 after purchasing an additional 6,190 shares during the last quarter. Finally, BKM Wealth Management LLC acquired a new stake in Becton, Dickinson and Company in the 4th quarter valued at about $1,043,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on BDX shares. Barclays raised their target price on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an “overweight” rating in a research note on Monday, February 5th. Raymond James raised their target price on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $279.17.

View Our Latest Stock Analysis on Becton, Dickinson and Company

Becton, Dickinson and Company Trading Up 1.1 %

Shares of BDX stock opened at $243.72 on Thursday. The firm has a 50 day moving average price of $240.08 and a two-hundred day moving average price of $244.35. The company has a quick ratio of 0.64, a current ratio of 1.08 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $70.41 billion, a PE ratio of 57.75, a price-to-earnings-growth ratio of 2.02 and a beta of 0.43. Becton, Dickinson and Company has a 12-month low of $229.85 and a 12-month high of $287.32.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last announced its earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 EPS for the quarter, topping the consensus estimate of $2.39 by $0.29. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The company had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.73 billion. During the same period last year, the firm earned $2.98 earnings per share. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. As a group, analysts predict that Becton, Dickinson and Company will post 12.94 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, March 29th. Stockholders of record on Friday, March 8th were issued a dividend of $0.95 per share. The ex-dividend date was Thursday, March 7th. This represents a $3.80 annualized dividend and a dividend yield of 1.56%. Becton, Dickinson and Company’s dividend payout ratio is presently 90.05%.

Insider Transactions at Becton, Dickinson and Company

In related news, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the transaction, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at $542,348.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.31% of the company’s stock.

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

See Also

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.